South Korea HIV Therapeutics Market Analysis Report [2022-30] I Insights10

South Korea HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the South Korea HIV therapeutics market will reach a value of $268.9 Mn from $201.1 Mn in 2022, growing at a CAGR of 3.7% during 2022-2030. The market is primarily dominated by local players such as Dong-A ST, Hanmi Pharmaceuticals, and Celltrion. The market for HIV/AIDS treatment in South Korea is primarily driven by government funding and initiatives, social issues like stigma and discrimination, and diagnostic tools. The HIV therapeutics market in South Korea is segmented by type, product, geography, end user, and distribution channel.

ID: IN10KRPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: South Korea AUTHOR: Dr. Vishwa Modhia

Buy Now

South Korea HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the South Korea HIV therapeutics market will reach a value of $268.9 Mn from $201.1 Mn in 2022, growing at a CAGR of 3.7% during 2022-2030. In South Korea, there are about 11,000 people who are HIV positive.

South Korea is ranked 53rd in the world for HIV prevalence among other nations. In 2019, the government of South Korea spent 8.2% of its GDP on healthcare. In South Korea, there were 975 newly discovered cases of HIV/AIDS in 2021. In South Korea, testing is done anonymously and without charge, and there are campaigns to keep raising awareness and lessen social stigma in the nation.

Highly Active Antiretroviral Therapy, also known as HAART, is the most common antiretroviral drug regimen used to treat HIV/AIDS in South Korea. These medications function by preventing the HIV virus from replicating within the body, which can aid in suppressing the virus to undetectable levels.

south korea HIV therapeutics market analysis

Market Dynamics

Market Growth Drivers Analysis

The number of people with HIV and AIDS is rising in Korea, despite the fact that there are fewer new HIV infections worldwide. HIV has become a "chronic" illness in Korea due to the developed nation's advanced medical technology. Even HIV-infected persons have normal lifespans, nearly 80 years for men.

Market Restraints

Due to the lack of anti-discrimination laws in South Korea, it is technically legal to discriminate against anyone based on their race, gender, ethnicity, or health, including their HIV status. One of the nations that still practice "AIDS denialism," or viewing this minority community with suspicion, is South Korea. Numerous people who are in urgent need of medical attention are dying as a result of increased stigmatization and discrimination. In South Korea, there were 178,653 HIV tests performed in 2020, down nearly 60% from 2019.

Competitive Landscape

Key Players

Dong-A ST (ROK)
Hanmi Pharmaceuticals (ROK)
Celltrion (ROK)
Yuhan Corporation (ROK)
Pfizer
Bristol-Myers Squibb
GlaxoSmithKline

Healthcare Policies and Reimbursement Scenarios

The Korea Disease Control and Prevention Agency's Division of HIV/AIDS Prevention and Control is responsible for managing HIV infection in South Korea. The AIDS Prevention Center for LGBTQ people run by the Korea Association for AIDS Eradication is known as the Ivan Stop HIV/AIDS Project (iSHAP). The National Health Promotion Fund and donations approved by the Korea Centres for Disease Control and Prevention and the Ministry of Health and Welfare are used to operate iSHAP.

For those who are unable to get tested at public health facilities or hospitals or who want LGBTQ-friendly counseling, iSHAP offers a free, anonymous, and expedited HIV test.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.